Thursday, February 08, 2018 11:46:59 AM
There is a confidentiality agreement in play for disclosure of certain financial info until 2019. It is on there SEC list of filings.
Or if DD aint your thing.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
April 3, 2014
ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Vantage Health
File No. 333-168930 - CF#30784
______________________
Vantage Health submitted an application under Rule 24b-2 requesting
confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed
on February 19, 2014.
Based on representations by Vantage Health that this information qualifies as
confidential commercial or financial information under the Freedom of Information Act,
5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly
disclose it. Accordingly, excluded information from the following exhibit(s) will not be
released to the public for the time period(s) specified:
Exhibit 10.1 through January 1, 2019
For the Commission, by the Division of Corporation Finance, pursuant to
delegated authority:
Kevin M. O’Neill
Deputy Secretary.
If that answer don't satisfy you feel free to write the company at their mailing address (it is how they tell us to contact them on the 10-k form).
My take on the CT agreement is interesting. Note the date is 2019 and the date of product release is expected to be 2018/2019. Big things are coming in a short time.
Or if DD aint your thing.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
April 3, 2014
ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Vantage Health
File No. 333-168930 - CF#30784
______________________
Vantage Health submitted an application under Rule 24b-2 requesting
confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed
on February 19, 2014.
Based on representations by Vantage Health that this information qualifies as
confidential commercial or financial information under the Freedom of Information Act,
5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly
disclose it. Accordingly, excluded information from the following exhibit(s) will not be
released to the public for the time period(s) specified:
Exhibit 10.1 through January 1, 2019
For the Commission, by the Division of Corporation Finance, pursuant to
delegated authority:
Kevin M. O’Neill
Deputy Secretary.
If that answer don't satisfy you feel free to write the company at their mailing address (it is how they tell us to contact them on the 10-k form).
My take on the CT agreement is interesting. Note the date is 2019 and the date of product release is expected to be 2018/2019. Big things are coming in a short time.
